Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drug Resistant Epilepsy Clear all
Completed Not applicable Interventional

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

NCT04770337
View directory record Official record
Conditions
Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Interventions
STARSTIM device, Sham Device
Device
Lead sponsor
Neuroelectrics Corporation
Industry
Eligibility
9 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Not listed No phase listed Observational

The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy

NCT02523183
View directory record Official record
Conditions
Epilepsy, Unspecified, Refractory (Medically)
Interventions
Medical Cannabis
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 20 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 5, 2026, 6:43 PM EST
Not yet recruiting Not applicable Interventional

EASEE® System Pivotal Study for the United States of America

NCT07301346
View directory record Official record
Conditions
Drug-Resistant Focal Epilepsy
Interventions
Implantable minimaly invasive brain stimulator
Device
Lead sponsor
Precisis US, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Helmet Design in Patients With Seizures

NCT03443388
View directory record Official record
Conditions
Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure, Fall Due to Seizure
Interventions
Hövding inflatable helmet
Device
Lead sponsor
Michael A. Gelfand, MD, PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Nov 5, 2026, 6:43 PM EST
Recruiting Phase 1 Interventional

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880
View directory record Official record
Conditions
Epilepsy
Interventions
Mangafodipir, Gadolinium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Completed Phase 1 Interventional

Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy

NCT06387186
View directory record Official record
Conditions
Refractory Epilepsy, Drug Resistant Epilepsy
Interventions
Leucine-Enriched Essential Amino Acid powder
Drug
Lead sponsor
Elizabeth Anne Thiele
Other
Eligibility
2 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Terminated Phase 1 Interventional

Brain Infusion of Muscimol to Treat Epilepsy

NCT00005925
View directory record Official record
Conditions
Epilepsy
Interventions
Muscimol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Nov 5, 2026, 6:43 PM EST
Active, not recruiting Not applicable Interventional

Memory Retrieval and Encoding Investigated by Neural Stimulation

NCT04286776
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Direct electrical stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 5, 2026, 6:43 PM EST
Completed Phase 2 Interventional Results available

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

NCT02758626
View directory record Official record
Conditions
Epilepsy
Interventions
ataluren, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 12 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Nov 5, 2026, 6:43 PM EST
Recruiting Not applicable Interventional

Infrared Photobiomodulation in Humans With Epilepsy

NCT07145489
View directory record Official record
Conditions
Drug Resistant Epilepsy
Interventions
photobiomodulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Recruiting Not applicable Interventional

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

NCT07680842
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions
Target optimization using LIFU, Serial LIFU stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Terminated Phase 3 Interventional Results available

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

NCT02519439
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Nov 5, 2026, 6:43 PM EST
Recruiting No phase listed Observational

Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

NCT07546253
View directory record Official record
Conditions
Drug Resistant Epilepsy, Refractory Epilepsy
Interventions
Participants are not assigned an intervention as part of the study.
Other
Lead sponsor
NeuroOne Medical Technologies Corporation
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Miami, Florida • Livingston, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Completed Phase 1 Interventional

Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy

NCT02286986
View directory record Official record
Conditions
Epilepsy
Interventions
Cannabidiol
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Years to 25 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Nov 5, 2026, 6:43 PM EST
Recruiting Not applicable Interventional

Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs

NCT06545643
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Dreem headband
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Recruiting Early Phase 1 Interventional

Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy

NCT05493722
View directory record Official record
Conditions
Refractory Epilepsy, Deep Brain Stimulation
Interventions
Physician-Selected Settings Stimulation, Optimized Settings Stimulation, DBS Setting Optimization
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Not listed Phase 4 Interventional

Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy

NCT01932502
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
clobazam (Onfi), Initial conversion and titration, Conversion schedule - Week 1, Conversion schedule - Week 2, Conversion schedule - Week 3
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Nov 5, 2026, 6:43 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NCT07222878
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Completed Phase 1 Interventional

Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits

NCT00181090
View directory record Official record
Conditions
Epilepsy
Interventions
Modified Atkins diet
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Nov 5, 2026, 6:43 PM EST
Completed Not applicable Interventional Results available

Optimal Stimulation Parameters to Disrupt Epileptiform Activity

NCT06141668
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
Neurostimulation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Active, not recruiting Not applicable Interventional Results available

Acute Recording of Stereotyped High-Frequency Oscillations

NCT05439655
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Interchange System
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Active, not recruiting Not applicable Interventional

Goals for Epilepsy Clinic Visits Trial

NCT05928598
View directory record Official record
Conditions
Drug Resistant Epilepsy
Interventions
Survey questionnaires, Epilepsy Visit Planner, Questionnaires for Providers
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 5, 2026, 6:43 PM EST
Terminated Phase 4 Interventional Results available

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

NCT04650204
View directory record Official record
Conditions
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 5, 2026, 6:43 PM EST